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Re-evaluating current antibiotic therapy 
W. A. CRAIG 
William S. Middleton Memorial VA Hospital, Madison, Wisconsin, U.S.A. 
Pharmacokinetic/pharmacodynamic (PK/PD) parameters derived from animal and clinical models of infection are 
used to predict bacteriological efficacy. Growing evidence from the clinical setting supports the validity of these 
parameters in guiding antimicrobial therapy. For example, in otitis media and sinusitis, high bacteriological cure 
rates are obtained when serum concentrations of p-lactams and macrolides exceed the MIC of the infecting 
pathogen for at least 40% of the dosing interval. Likewise, the 24-hour AUC/MIC ratio is a good predictor of both 
bacteriological and clinical efficacy for azithromycin in otitis media and fluoroquinolones in bacterial pneumonia. 
The value of PKjPD relationships has been recognized by the National Committee for Clinical Laboratory 
Standards (NCCLS) as another important factor to consider when establishing susceptibility breakpoints. Recent 
changes to NCCLS breakpoints for oral p-lactams for Streptococcus pneumoniue reflect this. Also, PKjPD 
parameters may play a role in predicting the impact of an antibiotic on the development and spread of resistant 
organisms. In an era of increasing resistance, we should select agents and doses that provide drug concentrations 
that exceed the magnitude of the PKjPD parameter required both for efficacy and to combat the emergence and 
spread of bacterial resistance. 
Key words: bacteriological eradication; nasopharyngeal carriage; pharmacodynamics; pharmacokinetics; pneumo- 
coccal resistance; susceptibility breakpoints. 
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Introduction 
Increasing antimicrobial resistance among common respira- 
tory pathogens (e.g. Streptococcus pneumoniae, Haemo- 
philus injluenzae and Moraxella catarrhalis) has the potential 
to reduce the efficacy of many oral drugs commonly used to 
treat respiratory infections (see Garau, ‘Clinical failures: the 
tip of the iceberg?, this issue) with patient and societal 
consequences. Thus, there is a need for a move towards 
preferentially using only those agents with suthcient potency 
and pharmacokinetic characteristics that will provide 
clinical activity against sensitive and resistant bacterial 
pathogens. In concert with this, measures to control 
colonization and infection with resistant organisms should 
also be undertaken. 
The goal of antimicrobial therapy is to maximize 
bacterial killing-simply inhibiting the pathogen may allow 
persistent colonization, recurrence of infection or permit 
the spread of resistant pathogens between individuals (1). 
The pharmacology of antimicrobial therapy can be divided 
into two distinct components-pharmacokinetics (PK) and 
pharmacodynamics (PD). PK refers to the absorption, 
distribution and elimination of drugs. These factors, 
combined with the dose regimen, determine the time course 
of antibiotic concentrations in serum which, in turn, 
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influence the time course of antibiotic concentrations in 
tissue and body fluids. The time course of drug concentra- 
tions at the site of infection is of key interest with respect to 
antimicrobial treatment. On the other hand, PD describes 
the relationship between serum concentrations and drug 
pharmacology and toxicology. For antimicrobial therapy, 
the relationship between concentration and antimicrobial 
effect is crucial (2). The inter-relationship between PK and 
PD determines the dosing duration and total dose required 
for optimal antimicrobial activity. 
This report offers an overview of the inter-relationship 
between PKjPD and efficacy for the various antimicrobial 
agents used for the treatment of RTIs. The value of PKjPD 
parameters in predicting the impact of antibiotic dose 
regimens on the selection of antibiotic resistance or 
maintenance of resistant clones is also examined. 
Nature of PK/PD parameters for 
common antibiotics 
Over the past decade, a number of studies have evaluated 
the predictive nature of PKjPD parameters with regard to 
in vivo bacteriological eradication. Specific PKjPD para- 
meters (e.g. peak’/MIC, AUC2/MIC ratio and time above 
MIC) have all been shown to be major determinants of 
‘Peak plasma concentration 
*Area under the serum concentration vwsus time curve 
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TABLE 1. PKjPD parameters predictive of bacteriological efficacy 
Antimicrobial effect PKjPD parameter Antimicrobial class 
Concentration-dependent killing and 
prolonged persistent effects 
Time-dependent killing and 
minimal-moderate persistent effects 
Time-dependent killing 
and prolonged persistent effects 
AUC/MIC 
or peak/MIC 
Time of dosing 
interval above MIC 
AUC/MIC 
Fluoroquinolones, aminoglycosides, 
ketolides 
Carbapenems, cephalosporins, 
clindamycin, macrolides, 
monobactams, oxazolidinones, 
penicillins 
Azithromycin, streptogramins, 
tetracyclines, vancomycin 
in viva antimicrobial activity. The specific PKjPD para- 
meter correlating with efficacy is largely dependent on 
whether bacterial killing is concentration or time depen- 
dent, and on whether there are prolonged, persistent effects 
(Table 1). These prolonged persistent effects are known as 
the post-antibiotic effect (PAE) and the post-antibiotic sub- 
MIC effect and result in the persistent suppression of 
bacterial growth following exposure to an antimicrobial 
agent. 
For p-lactams, macrolides and clindamycin, the duration 
of time that serum concentrations exceed the MIC (time 
above MIC) provides the most accurate prediction of 
bacteriological efficacy. In contrast, for drugs such as 
fluoroquinolones and azithromycin, the AUC/MIC ratio is 
most important. Thus, even if a fluoroquinolone and a p- 
lactam had the same in vitro activity for a given pathogen, 
there would be marked differences in the PD that would be 
important in determining the optimal dose regimen (1). 
Magnitude of PK/PD parameters 
governing antimicrobial efficacy 
/sLACTAMS 
As /3-lactams have a kill rate that is independent of 
concentration, concentrations higher than the MIC or 
MBC do not greatly increase bacterial kill. Thus, the dosing 
regimens should maximize the duration of time that serum 
drug levels exceed the MIC (2,3). Studies performed in 
murine models of 5’. pneumoniae thigh and pneumonia 
infections, using amoxicillin + clavulanate, have shown that 
bactericidal activity occurs once the duration of time starts 
to exceed 40% above the MIC in a 24- or 48-hour period 
(Fig. 1) (4,5). This requirement is independent of the 
infecting pathogen and its resistance profile. 
The double tympanocentesis method has been a useful 
tool in investigating the clinical relevance of PKjPD 
parameters for otitis media. In this method, a sample of 
middle ear fluid is taken just prior to antimicrobial therapy 
and then again 4-6 days after therapy has commenced and 
during follow-up when a clinical relapse occurs. This 
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FIG. 1. Relationship between time above MIC and efficacy 
for amoxicillin against S. pneumoniae in murine pneumonia 
and thigh-infection models (4,5). 0: pneumonia, 48 h; 0: 
thigh, 24 h. 
technique allows the bacteriological efficacy of antimicro- 
bials to be directly measured and compared. As a result, 
much of the clinical data that are available supporting the 
validity of PKjPD parameters comes from studies in acute 
otitis media. Some data are also available from studies in 
sinusitis. Here, a sample of sinus fluid is taken prior to 
antibiotic therapy and then again about 7-10 days after the 
start of therapy. 
Using data from studies in both otitis media and 
sinusitis, time above MIC for each of the dose regimens 
was calculated from mean serum concentrations and the 
MICs for different organisms were taken from the 
literature. Figure 2 illustrates the relationship between the 
time above MIC and bacteriological cure for many p- 
lactam agents in these two infections. High rates of 
bacteriological cure (> 80%) were achieved once the time 
above MIC exceeded 40%. Most of the S. pneumoniae 
isolates were penicillin susceptible, hence the high bacter- 
iological cure rate, which approaches 100% (6). Interest- 
ingly, the effect of time above MIC on bacteriological 
efficacy was independent of infection, which further 
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supports the general utility of PKjPD parameters in 
predicting bacteriological efficacy. 
Assuming that a time above MIC of at least 40% is 
required for optimal bacteriological efficacy, then the effect 
of increased MICs due to antimicrobial resistance can be 
predicted (Table 2). Most of the currently available fl- 
lactam antimicrobial agents provide adequate times above 
the MIC for bactericidal activity against penicillin-suscep- 
tible strains of S. pneumoniae. However, against penicillin- 
intermediate S. pneumoniae, only amoxicillin f clavulanate 
(875 mg/125 mg b.d. or 500 mg/125 mg t.d.), cefuroxime 
(500mg b.d.) and ceftriaxone (1 g o.d.) exceed the MIC for 
at least 40% of the dosing interval (Table 2). Notably, 
cefaclor (500 mg t.d.) and cefixime (400mg o.d.) do not 
exceed the MIC for the entire dosing interval and would, 
therefore, be ineffective against as many as 90% of these 
pathogens. Against penicillin-resistant S. pneumoniae, only 
ceftriaxone would be predicted to be effective against most 
strains based on time above MIC data and amoxicillink 
clavulanate would be the only oral B-lactam providing 
too 
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FIG. 2. Relationship between time above MICw and 
bacteriological cure for S. pneumoniae and H. inzuenzae 
in the treatment of otitis media and acute maxillary 
sinusitis. 0, n : S. pneumoniae; 0, 0: H. injuenzae; l , 
0: otitis media; n , 0: acute maxillary sinusitis. Repro- 
duced with permission (6). 
coverage against a significant proportion of these strains, 
the other oral fl-lactams being largely ineffective 
(i.e. time> MICaa = 0). These predictions are supported 
by clinical data in otitis media. For example, in a study 
by Dagan et al., bacteriological efficacy with cefaclor 
(40 mg kg-’ day-i) in cases due to penicillin-susceptible 
S. pneumoniae was 81% compared with 100% for 
amoxicillin (49.5 mg kg-’ day- ‘). However, in those pa- 
tients infected with penicillin non-susceptible S. pneumo- 
niae, bacteriological efficacy with cefaclor was only 35%, 
but was still as high as 71% for amoxicillin against these 
strains (7). Similarly, in a separate study with amoxicillin/ 
clavulanate (45/6.4 mg kg-’ day-‘) in children with otitis 
media, the drug was highly effective, even against strains 
with MICs of 2,~~grnl-’ and higher (8). 
For H. injluenzae, there are wide variations among the /?- 
lactams in the percentage of time above MIC achieved 
(Table 2). Several of the cephalosporins (e.g. cefaclor, 
cefuroxime and cefprozil) do not provide sufficient serum 
levels to achieve a 40% time above MIC, and are unlikely 
to exhibit high bacteriological efficacy. Using the same 
study as above as an example, for those patients infected 
with H. injfuenzae, the bacteriological failure rate with 
cefaclor was 50% compared with 27% for amoxicillin (7). 
However, the failure rate with amoxicillin was 60% against 
strains producing p-lactamase compared with 21% for p- 
lactamase negative strains, clearly illustrating the effect of 
resistance on antimicrobial efficacy (7). 
MACkOLIDES 
For the older macrolides (e.g. erythromycin and clarithro- 
mycin), as for the p-lactams, time above MIC is predictive 
of bacteriological efficacy (3). For optimal efficacy, macro- 
lide serum concentrations should exceed the MIC of the 
infecting pathogen for 40&50% of the dosing interval. 
Although the azalide, azithromycin, does not exhibit 
concentration-dependent killing, the AUC/MIC ratio 
correlates with bacteriological efficacy. This may be due 
to the much longer in vivo PAEs produced by azithromycin, 
in comparison with other macrolides or fl-lactams (2). For 
azithromycin, the 24-hour AUC/MIC ratio needs to exceed 
TABLE 2. Time above MICsa (T > MIC) for oral p-lactams against penicillin-susceptible (PSSP), -intermediate (PISP) and 
-resistant S. pneumoniae (PRSP) and H. injhenzae 
Antimicrobial Regimen (mg) T>MIC 
PSSP PISP PRSP H. injkenzae 
Amox/clav 8751125 b.d. 100 50 32 42 
Cefaclor 500 t.d. 46 0 0 0 
Cefuroxime 500 b.d. 73 41 0 35 
Cefprozil 500 b.d. 78 38 0 18 
Cefpodoxime 200 b.d. 62 32 0 82 
Cefixime 400 o.d. 48 0 0 88 
Ceftriaxone 1000 o.d. 100 78 42 100 
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25 for optimal efficacy. This value is comparable to 
averaging one times the MIC over a 24-hour period. 
Although it is often argued that for macrolides tissue rather 
than serum levels determine efficacy, it must be remembered 
that the major respiratory tract pathogens are found 
primarily in extracellular sites. Thus, the high concentration 
of macrolides intvacellulurly decreases the potential of 
achieving therapeutic concentrations at the extracellular 
site of infection (9). 
In the clinical setting, double tympanocentesis studies in 
pediatric AOM using erythromycin and clarithromycin 
have shown that standard doses of these agents produce 
drug serum levels which exceed the Ml&, for susceptible 
strains of S. pneumoniae for S&100% of the dosing interval 
(10). Correspondingly, the bacteriological cure rates are 
high-93% for erythromycin and 100% for clarithromycin 
(11). Against susceptible strains of S. pneumoniue, the 
AUC/MIC ratio for a standard dose of azithromycin is 50. 
By contrast, for macrolide-resistant strains, the AUC/MIC 
ratio for azithromycin is less than 0.1, predicting poor 
efficacy against these strains. This has been shown 
clinically, with a high bacteriological cure rate of 92% for 
azithromycin against macrolide-susceptible S. pneumoniae 
compared with only 38% against macrolide-resistant 
strains (8). This low rate of cure is almost the same as 
that observed with placebo, where around 20% of patients 
have spontaneous eradication of the infecting pathogen 
(12). 
There is growing evidence that, even though MICs for 
macrolides against H. iq?uenzae may be in the ‘susceptible’ 
range (as defined by current MIC breakpoints), in vivo 
bacteriological efficacy is poor against this pathogen. For 
example, against strains of H. injluenzae with clarithromy- 
tin or erythromycin MICs of 4 ,ugml-‘, the time above 
MIC would be 0% of the dosing interval for both of these 
agents at standard dosing regimens. For azithromycin, a 
similar situation has been observed. For example, against 
H. irfluenzae with azithromycin MICs of 0.5->2pgmll’ 
(i.e. susceptible), the rate of bacteriological failure was as 
high as 61%. Moreover, when only those isolates with 
MICs > 2 pg ml-’ were included, bacteriological failure 
increased to 78% (8). This is consistent with PKjPD 
predictions, as an azithromycin MIC against H. injluenzae 
of 2pgmll’ would give an AUC/MIC ratio of ~2, well 
below the value of 25 required for bacteriological efficacy. 
FLUOROQUINOLONES 
The 24-hour AUC/MIC ratio is predictive of bacteriologi- 
cal efficacy for the fluoroquinolones (3), and is independent 
of the dosing interval, the fluoroquinolone used and the site 
of infection (2). The magnitude of this parameter required 
for bacteriological efficacy varies according to the infecting 
pathogen-for S. pneumoniae AUC/MIC needs to be 25- 
30. In comparison, for Gram-negative bacilli (e.g. Escher- 
ichia coli), particularly those causing nosocomial infections, 
the AUC/MIC ratio needs to reach 100; that is, serum levels 
need to average around four times the MIC over a 24-hour 
period (2). 
A variety of fluoroquinolones have been evaluated in 
animal models of infection using mortality as the endpoint. 
In studies involving immunocompetent animals infected 
with S. pneumoniae, there was low mortality at AUC/MIC 
ratios of 25 and above (13). By contrast, similar work in 
immunocompromised animals, where the infections were 
caused by various Gram-negative bacteria (E. coli, Kleb- 
siella spp. and Pseudomonas spp.), indicated that levels of 
survival became significant only when AUC/MIC ratios 
reached 100 or above (14). 
These findings are supported clinically. Two studies have 
investigated the relationship between PKjPD and efficacy 
of ciprofloxacin and levofloxacin (15,16). Forrest et al. 
retrospectively analyzed 64 seriously ill patients who were 
treated with intravenous ciprofloxacin at doses ranging 
from 200mg b.d. to 400mg t.d. (15). A population PKjPD 
analysis relating drug exposure to infectious outcome was 
determined. Data revealed that a 24-hour AUC/MIC ratio 
of 125 was required for favorable clinical and bacteriolo- 
gical outcome. For those patients who had an AUC/MIC 
ratio of < 125 (n= 19) the probability of clinical or 
microbiological cure was 42% and 26%, respectively (15). 
At an AUC/MIC ratio of 2125 (n = 45), however, the 
probability of clinical cure increased to 80% (P~O.005) 
and microbiological cure to 82% (P<O.OOl), respectively. 
Preston et al. conducted a prospective study of 134 patients 
with infections of the skin or urinary or respiratory tract of 
mixed microbial etiology (16). Patients were treated with 
intravenous levofloxacin, 250-500 mg every 24 hours for at 
least three doses. The probability of both clinical and 
microbiological cure was significantly higher (P<O.OOl), 
when the peak/MIC ratio was at least 12.2. This value is 
comparable with a 24-hour AUC/MIC ratio of 100 (16). 
Relevance of PKE’D and NCCLS 
breakpoints for oral agents 
S. PNE UMONIAE 
The value of PKjPD relationships has been recognized by 
the National Committee for Clinical Laboratory Standards 
(NCCLS) as an important factor to consider when 
establishing susceptibility breakpoints. New NCCLS break- 
points, issued in January 2000, for oral p-lactams for S. 
pneumoniae reflect the impact of PKjPD relationships 
(Table 3) (17). 
For fl-lactam antibiotics, only two oral agents were 
previously designated NCCLS breakpoints for S. pneumo- 
niae-amoxicillin and cefuroxime (both 0.5 pgrnl-I). With 
a target PKjPD value of 40% time above MIC for 
predicted efficacy, a PKjPD breakpoint can be calculated. 
Thus, S. pneumoniae NCCLS susceptibility breakpoints 
were set at 2 pg ml-’ for amoxicillin and 1 pg ml- ’ for 
cefuroxime to more accurately reflect the in vivo bacter- 
iological efficacy of these agents. Breakpoints have also 
been set for cefaclor (1 pgmll’), cefprozil (2 pgml-‘) and 
cefpodoxime (0.5,ngml-I), though as yet there is no 
NCCLS breakpoint for cefixime (PK/PD breakpoint 
0.5,ugmll’). 
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TABLE 3. Pharmacodynamic (PD) and old and new NCCLS susceptibility breakpoints for various oral B-lactam antimicrobial 
agents with S. pneumoniae (17) 
Drug Old NCCLS breakpoint 
(mmlpl) 
PD breakpoint 
bgml-‘) 
New NCCLS breakpoint 
(,aml-‘) 
Amoxicillin 0.5 2 2 
Cefaclor 0.5 1 
Cefuroxime 0.5 1 1 
Cefprozil - l-2 2 
Cefpodoxime - 0.5 0.5 
Cefixime - 1 - 
The NCCLS breakpoints for both clarithromycin and 
erythromycin of 0.25 pgml-’ are in line with PKjPD 
breakpoints. For the azalide, azithromycin, in order to 
achieve an AUC/MIC ratio of 25, the PKjPD breakpoint 
for S. pneurnoniae would be 0.12 pg ml- ‘. This is two 
doubling dilutions lower than the current NCCLS break- 
point of 0.5 pg ml-‘. 
For the fluoroquinolones, NCCLS breakpoints are only 
available at present for levofloxacin (2 ,ug ml-‘), sparflox- 
acin (0.5 pg ml-‘), ofloxacin (2 pg ml- I), grepafloxacin 
(0.5 pg ml-‘) and trovafloxacin (1 pg ml-‘). These break- 
points are generally in line with PKjPD breakpoints 
calculated to achieve a 24-hour AUC/MIC ratio of 25-30. 
H. INFLUENZAE 
There are varying degrees of discrepancy between NCCLS 
breakpoints for H. injuenzae and calculated PKjPD 
breakpoints for different antibiotic agents (Table 4). For 
the /$lactams, cefaclor shows the greatest difference in 
NCCLS veTsus PKjPD breakpoint. The clinical effect of 
this difference was shown in a recent double tympanocen- 
tesis study by Dagan et al. in patients with otitis media (18). 
With a dose of 40 mg kg-’ day-’ cefaclor, they reported a 
high bacteriological failure rate for H. injuenzae of 50% 
(15/30). This is despite all the H. inzuenzae isolates being 
susceptible to cefaclor using NCCLS breakpoints (18). 
From these findings, the investigators determined that the 
clinically relevant breakpoint for cefaclor was 0.25 pg ml- ‘, 
which is closer to the PKjPD breakpoint (18). 
For both clarithromycin and azithromycin, the PKjPD 
breakpoint is five doubling dilutions lower than the 
NCCLS breakpoint. Again, there is evidence from studies 
in otitis media supporting the clinical relevance of the PK/ 
PD parameter. For example, in the same recent study as 
above, 17 of 35 (49%) patients treated with 
10 mg kg- ’ day- ’ azithromycin experienced bacteriological 
failure (18). The low bacteriological efficacy of azithromy- 
tin against H. injuenzae has been confirmed in another 
recent study in which azithromycin (10 mg kg-’ on day 1, 
then Smgkgg’dayy’ for 4 days) failed to eradicate H. 
influenzae in 61% of patients (8). In both these studies, all 
isolates were susceptible to azithromycin using the NCCLS 
TABLE 4. Pharmacodynamic (PD) and NCCLS suscept- 
ibility breakpoints for various oral antimicrobial agents 
with H. injuenzae 
Drug PD breakpoint NCCLS Dilutions 
(iczml-‘) breakpoint difference 
bug ml-9 
Amoxicillin 
Cefaclor 
Cefuroxime 
Cefprozil 
Cefpodoxime 
Cefixime 
Erythromycin 
Clarithromycin 
Azithromycin 
2 4 
0.5 8 
1 4 
l-2 8 
0.5 2 
1 1 
0.25 NA 
0.25 8 
0.12 4 
1 
4 
2 
4-2 
1 
0 
- 
5 
5 
breakpoint. Similar failure rates to those seen with 
azithromycin have also been observed for clarithromycin 
(19). These data indicate the lack of clinical relevance of 
current NCCLS breakpoints for the macrolides against H. 
infuenzae in otitis media. Based on clinical data, Dagan et 
al. recommend a breakpoint of 0.12 pgml- ’ for azithro- 
mycin against H. inJuenzae, in line with the PKjPD 
breakpoint (18). However, clarithromycin and azithromy- 
tin provide higher concentrations in the lungs than in 
middle ear fluid, which may allow higher susceptibility 
breakpoints when treating pulmonary infections with these 
drugs. 
Elimination of resistant pathogens 
from the nasopharynx 
The nasopharynx acts as a reservoir of infection and a 
source for the dissemination of resistant isolates. Recent 
studies show that children treated with a course of 
antimicrobial medication have a greater risk of becoming 
carriers of non-susceptible pneumococci (20,21). Although 
prescribers recognize the problem of antibiotic resistance, 
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unnecessary or inappropriate prescription of antimicrobial 
agents is common (22). When the use of an antibiotic is 
warranted, clinicians must consider the agent’s ability to 
eradicate non-susceptible pathogens not only from the site 
of infection, but also from the nasopharynx. 
A French study involving a group of children with acute 
otitis media evaluated the impact of 10 days’ treatment with 
either cefixime suspension (8 mg kg-’ day-’ b.d.) or 
amoxicillin/clavulanate suspension (80 mg kg-’ day-’ t.d.) 
on the eradication of S. pneumoniue from the nasopharynx 
(23). Using PKjPD parameters, amoxicillin/clavulanate 
would be expected to be superior in eradicating penicillin- 
non-susceptible S. pneumoniae. A total of 224 patients were 
carrying S. pneumoniae at enrollment-l 17 (48 PRSP) were 
treated with cefixime and 107 (54 PRSP) with amoxicillin/ 
clavulanate. At end of treatment, significantly fewer 
children receiving amoxicillin/clavulanate were carriers of 
S. pneumoniae-including PRSP--compared with those 
receiving cefixime (21 versus 95, P< 0.001). This represents 
an 80% reduction in the carriage of S. pneumoniae with 
amoxicillin/clavulanate compared with only 19% with 
cefixime. Of those patients carrying S. pneumoniue at end 
of therapy, 48 in the cefixime group carried PRSP strains 
compared with just 21 patients in the amoxicillin/clavula- 
nate group (23). This represents a 69% reduction in the 
carriage of PRSP with amoxicillin/clavulanate, compared 
with a 0% reduction in PRSP carriage with cefixime. These 
results are exactly in line with predictions made based on 
PKjPD parameters. 
A study by Cohen et al. (24) compared a single, 
intramuscular injection of ceftriaxone (50 mg kg-‘) with 
10 days of treatment with amoxicillin/clavulanate 
(10mgkgg’day-’ t.d.) on the nasopharyngeal carriage of 
S. pneumoniae in children with AOM. Using PKjPD 
parameters, both of these agents would be expected to 
display high bacteriological efficacy. Before treatment, 65 
and 78 children receiving ceftriaxone and 71 and 80 
receiving amoxicillin/clavulanate were carriers of suscepti- 
ble and non-susceptible strains of S. pneumoniae, respec- 
tively. However, at the end of treatment, significantly fewer 
children receiving amoxicillin/clavulanate were carriers of 
S. pneumoniae-including PRSP-compared with those 
receiving ceftriaxone (41 versus 99, P<O.OOOl). A total of 
63 children in the ceftriaxone group were carriers of non- 
susceptible S. pneumoniae compared with just 34 in the 
amoxicillin/clavulanate group (P = 0.02). This difference 
may be explained to some extent by the fact that, in the case 
of ceftriaxone, swabs were taken from the nasopharynx at 
10 days. Thus, drug levels with a single dose of ceftriaxone 
were above the MIC for only about 2 of the 10 days, so the 
duration of time above MIC was actually inferior to that 
obtained with amoxicillin. 
Based on the data above on the eradication of 
nasopharyngeal carriage of PSSP and PRSP, serum 
concentrations need to exceed the MIC for about 
80-100% of the dosing interval to achieve high rates of 
eradication. Current dose regimens may not be sufficient to 
achieve this requirement. New formulations, which deliver 
higher doses, are being developed to ensure that target PK/ 
PD values can be reached. For example, a new 901 
6.4mgkgg’dayy’ suspension formulation of amoxicillin/ 
clavulanate has been developed specifically for this purpose. 
Data have not yet been reported on the effect of this 
formulation on nasopharyngeal carriage. However, initial 
bacteriological efficacy results in otitis media are encoura- 
ging (25). In a recently reported study, 351 patients with 
AOM had pathogens isolated at screening. Overall, 54% of 
the 146 isolates of S. pneumoniae detected were penicillin 
susceptible, with 17% intermediate and 29% resistant. Of 
the patients with S. pneumoniae infection, 114 had repeat 
typanocentesis that was positive for S. pneumoniae. Treat- 
ment with high-dose amoxicillin/clavulanate resulted in 
eradication of S. pneumoniae in 99% of these patients at 
end of therapy (25). 
Inappropriate antibiotic therapy can increase the prob- 
ability of continued nasopharyngeal carriage and the risk of 
harboring resistant strains. For example, a study conducted 
in children in Iceland found that the odds ratio for carriage 
of penicillin-resistant pneumococci, after three or more 
courses of antibiotic therapy, was 12 with erythromycin or 
co-trimoxazole, compared with only 6 for fl-lactams (26). 
This indicates that erythromycin was a more potent selector 
of penicillin resistance than p-lactams in this community. 
This is because the particular clone of S. pneumoniae in 
these individuals was resistant to multiple agents. Here, the 
use of one antibiotic class, in this case macrolides and 
co-trimoxazole, can select for resistance to another classes 
of agent, in this case penicillin (26). 
Emergence or selection of resistant 
mutants 
The application of pharmacodynamic concepts suggests 
that bacterial exposure to low and prolonged concentra- 
tions of antimicrobial agents may have a role in the 
selection of resistant strains. Analysis of macrolide 
prescribing and resistance patterns in S. pneumoniae 
indicates a correlation between increasing macrolide 
resistance and the use of newer, long-acting macrolides 
(e.g. azithromycin and clarithromycin) (27). These agents 
have long half-lives, and serum concentrations do not 
exceed the MIC throughout the dosing interval. This may 
increase the potential for the induction of antibiotic 
resistance. Further evidence of the impact that macrolides 
may have on resistance development comes from Iceland 
(28). As discussed above, in this country, the predominant 
drug-resistant S. pneumoniae clone (type 6B) is multi- 
resistant to a number of agents and macrolides have been 
shown to select for penicillin resistance in this organism 
(26). The consumption of macrolides and co-trimoxazole 
has fallen by 30% since 1990. This has coincided with a 
decrease in penicillin-resistant S. pneumoniae from a peak 
prevalence of 20% in 1992 to 13% in 1997 (28). There was 
no major change in the use of p-lactams during this period 
(< 10%). 
Various PKjPD parameters have been proposed as 
indicators for the potential of antibiotics to induce 
resistance mutations. For example, for fluoroquinolones, 
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the ratio between the peak serum concentration and the 
MIC, termed the inhibitory quotient, may be relevant. The 
higher the inhibitory quotient, the lower the potential for 
resistance selection-an inhibitory quotient lower than 4 is 
thought to indicate a high potential for resistance selection. 
Recent interest has been directed towards experiments to 
determine the mutation prevention concentration (MPC). 
This is the lowest concentration of drug that will prevent 
selection of any mutants in very large inocula. Initial 
studies suggest that the magnitude of the MPC varies 
according to the organism and to the antimicrobial agent 
used (29). Generally, MPC values for fluoroquinolones 
range from 4 to 10 times the MIC. Previous studies in 
humans and in animal models of infection have demon- 
strated that peak concentrations of 8-10 times the MIC can 
prevent the emergence of resistant mutants (30,31). 
Conclusion 
The PKjPD parameters are useful for predicting antibiotic 
efficacy in RTIs and can, therefore, be used in a variety of 
ways to optimize the use of these agents. They provide a 
valuable basis for recommendations in therapeutic guide- 
lines, such as the DRSP Working Group guidelines for 
otitis media (32), pneumonia (33) and the recent American 
Academy of Otolaryngology, Head and Neck Surgery 
sinusitis guidelines (34) and have a key role to play in 
establishing susceptibility breakpoints, as witnessed by their 
inclusion in recent NCCLS criteria for establishing new 
breakpoints for S. pneumoniae (17). 
It is now well accepted that currently available antibiotics 
vary significantly in their ability to achieve the PKjPD 
values necessary for bacterial eradication, particularly in 
the case of resistant strains. Appropriate antimicrobial 
choice (choice of agent, dose and duration) should be based 
on the ability to eradicate pathogens from the site of 
infection and from the nasopharynx using PKjPD princi- 
ples and local susceptibility data as a guide to effective 
therapy. 
In conclusion, the judicious use of antimicrobial agents 
should permit the clinician to prescribe from a selection of 
agents which maximize bacteriological and clinical cure, 
and which minimize the emergence and spread of resistant 
pathogens. 
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